COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration (FDA) issued updated guidance this month related to its emergency use authorizations for N95 respirator decontamination systems. The authorization now limits respirator reuse to no more than four times.
According to the Centers for Disease Control and Prevention (CDC), a more highly transmissible variant of SARS-CoV-2, B.1.1.7, has been detected in 12 U.S. states, putting the country at risk for a rise in COVID-19 cases, hospitalizations and deaths.
To reduce the risk of false negative results for COVID-19, the FDA issued guidance this week for safely using the Curative SARS-CoV-2 test.
Anaphylaxis, a life-threatening allergic reaction, occurred in 11.1 cases per million doses of Pfizer-BioNTech COVID-19 vaccine administered in the United States during the week of Dec. 14, 2020.
The Department of Health and Human Services (HHS) posted two requests for information last week.
New evidence suggests breast milk is not a likely source of SARS-CoV-2 transmission, according to a recent update from the Centers for Disease Control and Prevention (CDC)
This week the Food and Drug Administration (FDA) granted emergency use authorization for the first rapid home-based test for SARS-CoV-2.
Hospitalization rates are roughly four times higher for Black, Hispanic and Native American people infected with COVID-19 than for whites
In a study of 106,543 patients hospitalized for COVID-19 between March and July, 9% were readmitted to the same hospital